{"entity":{"id":"prcc","kind":"target","name":"PRCC","aka":["proline rich mitotic checkpoint control factor","Proline-rich protein PRCC","RCCP1"],"tldr":"PRCC (Proline-rich protein PRCC) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","summary":"May regulate cell cycle progression through interaction with MAD2L2.\n\nOpen Targets scores its association with cancer at 0.54 (direct and indirect evidence; datatypes literature 0.96, genetic association 0.23, somatic mutation 0.80).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:9343","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9343"},{"label":"UniProt Q92733","url":"https://www.uniprot.org/uniprotkb/Q92733/entry"},{"label":"NCBI Gene 5546","url":"https://www.ncbi.nlm.nih.gov/gene/5546"},{"label":"Ensembl ENSG00000143294","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143294"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03091192","nct05043090"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier \"association-only\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"PRCC","role":["fusion-partner"],"evidenceTier":"association-only","sources":[{"label":"HGNC HGNC:9343","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9343","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q92733","url":"https://www.uniprot.org/uniprotkb/Q92733/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000143294","url":"https://platform.opentargets.org/target/ENSG00000143294/associations","note":"association with cancer (MONDO_0004992) 0.54;  (GraphQL API, CC0)"}],"hgnc":"HGNC:9343","ensembl":"ENSG00000143294","uniprot":"Q92733","entrez":"5546","biology":"May regulate cell cycle progression through interaction with MAD2L2. Location: Nucleus (UniProt). Locus 1q23.1 (HGNC).","whereFound":[],"targetClass":"other","prevalence":[]},"route":"/targets/prcc/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"trial":[{"id":"nct05043090","kind":"trial","name":"Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC","route":"/trials/nct05043090/"},{"id":"nct03091192","kind":"trial","name":"Savolitinib vs. Sunitinib in MET-driven PRCC.","route":"/trials/nct03091192/"}]}}